Across all the IGF-1/R inhibitors, 16.9% of treated patients experienced any otologic AEs, including 1.6% with hearing AEs, 1.7% with tinnitus AEs, 11.4% with dizziness or vertigo AEs, and 2.2% with other otologic AEs (Table 2). The gene discussed is IGF1R; the disease is Tinnitus.